Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 47, 1751-1755, April 1, 1987]
© 1987 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gout, P. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Gout, P. W.

Transient Requirement for Prolactin as a Growth Initiator following Treatment of Autonomous Nb2 Node Rat Lymphoma Cell Cultures with Butyrate1

Peter W. Gout

Department of Cancer Endocrinology, Cancer Control Agency of British Columbia, Vancouver, British Columbia, Canada V5Z 4E6

A previous study described the development of cultures of Nb2 node rat lymphoma cells which specifically require a lactogenic hormone, e.g., prolactin (PRL), as a growth factor. In the present study, sublines of these cultures have been established, including clones, which do not depend on exogenous lactogens for growth; the cells do not appear to produce autocrine, PRL-like substances. Although these autonomous cells grew readily in the complete absence of lactogens, their growth rate was stimulated (up to approximately 30%) by PRL concentrations >=0.1 ng/ml. When cultures of the lactogen-dependent and of the cloned, autonomous lymphoma cells were incubated for 3 days with sodium n-butyrate (NaBT; 2 mM), cells were arrested in the G1 phase of the cell cycle, as shown by flow cytometric analysis. A substantial proportion of the G1-arrested cells was viable and readily resumed growth, within 1 day, when transferred to NaBT-free medium containing PRL (1–100 ng/ml). The resumption of growth of the cells from the lactogen-dependent cultures was critically dependent on PRL; in its absence cells lysed. Surprisingly, the rapid recovery of the cells from the lactogen-independent cultures also depended on the presence of PRL in the medium; in its absence growth did not resume for at least 2.3 days. The acquired need of the NaBT-treated, autonomous cells for PRL was only transient, since such cells reverted fully to the PRL-independent state within about 3 days of culturing in PRL-containing, NaBT-free medium. It is proposed, as a working hypothesis, that the autonomous lymphoma cells can be mitogenically activated by two different pathways, one requiring exogenous lactogens and another which is independent of lactogens; the latter pathway recovers much more slowly from the treatment with NaBT than the lactogen-dependent pathway. This model could explain the sensitivity of the autonomous lymphoma cells to PRL and their transient dependency on exogenous lactogens during their recovery from NaBT treatment. NaBT would appear to be a useful agent for studying the mechanism(s) by which the autonomous lymphoma cells circumvent the need for mitogenic lactogens.

1 This study was supported by a grant from the National Cancer Institute of Canada.

Received 1/20/86. Revised 8/18/86. Revised 12/ 3/86. Accepted 1/ 2/87.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. Rider, A. Shatrova, E. P. Feener, L. Webb, and M. Diakonova
JAK2 Tyrosine Kinase Phosphorylates PAK1 and Regulates PAK1 Activity and Functions
J. Biol. Chem., October 19, 2007; 282(42): 30985 - 30996.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Karp, H. Pan, M. Zhang, D. J. Buckley, L. A. Schuler, and A. R. Buckley
Identification of HRPAP20: A Novel Phosphoprotein that Enhances Growth and Survival in Hormone-Responsive Tumor Cells
Cancer Res., February 1, 2004; 64(3): 1016 - 1025.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
A R Buckley
Prolactin, a lymphocyte growth and survival factor
Lupus, October 1, 2001; 10(10): 684 - 690.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
M. J. Blake, A. R. Buckley, M. Zhang, D. J. Buckley, and K. P. Lavoi
A Novel Heat Shock Response in Prolactin-dependent Nb2 Node Lymphoma Cells
J. Biol. Chem., December 8, 1995; 270(49): 29614 - 29620.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1987 by the American Association for Cancer Research.